ARCA DISCOVERY CHANGES NAME TO ARCA BIOPHARMA TO REFLECT FOCUS ON DRUG COMMERCIALIZATION
Company Appoints Randall St. Laurent as EVP of Commercial Operations

Arca Discovery, Inc. to present at 26th annual JPMorgan healthcare conference on January 8th, 2008.
January 4th, 2008

Arca Discovery, Inc. announces data demonstrating potential for Bucindolol as targeted therapy in heart failure, atrial fibrillation, and ventricular arrhythmia.
November 6th, 2007

Arca Discovery, Inc. completes $18 million equity financing to advance targeted cardiovascular therapies and submit lead product for approval this year.
June 8th, 2007

Arca Discovery, Inc. Announces Appointment of J. William Freytag, PH.D. to its Board of Directors
March 9th, 2007

Arca Discovery and LabCorp® partner to commercialize companion diagnostic for first cardiovascular personalized medicine
February 13th, 2007

ARCA Discovery, Inc. Names Richard B. Brewer President and Chief Executive Officer
November 6, 2006

ARCA Discovery, Inc. Names Thomas Keuer Executive Vice President of Pharmaceutical Operations
October 30, 2006

ARCA Discovery, Inc. Announces Publication of the Genetic Basis for Enhanced Response to Bucindolol
July 17, 2006

ARCA Discovery, Inc. Names Dr. Ann Lenich Hards Executive Vice President Regulatory Affairs
July 10, 2006

ARCA Discovery, Inc. Raises $15 Million In Series A Financing
March 2, 2006